{"id":"placebo-and-saizen","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Carpal tunnel syndrome"},{"rate":null,"effect":"Fluid retention"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Saizen® (somatropin) is a synthetic form of human growth hormone (hGH) produced via recombinant DNA technology. It binds to growth hormone receptors on target tissues, stimulating linear growth, protein synthesis, and lipolysis while affecting carbohydrate and mineral metabolism. The trial appears to be comparing Saizen® efficacy and safety against placebo in a growth hormone-deficient or growth-related indication.","oneSentence":"Saizen® is a recombinant human growth hormone that replaces or supplements endogenous growth hormone to promote growth and metabolic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:37.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency (likely indication based on Saizen® approved uses)"},{"name":"Short stature or growth disorders (potential Phase 3 indication)"}]},"trialDetails":[{"nctId":"NCT07359625","phase":"NA","title":"Effects of Ketone Bodies on Insulin Sensitivity","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2025-12-02","conditions":"Insulin Resistance, Obesity & Overweight, Energy Metabolism","enrollment":10},{"nctId":"NCT07016802","phase":"PHASE1","title":"A Clinical Study of GenSci134 in Healthy Male Adults","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-06-23","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT01562834","phase":"PHASE4","title":"Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-10-21","conditions":"Growth Hormone Disorder, Adult Growth Hormone Deficiency","enrollment":22},{"nctId":"NCT04121780","phase":"PHASE2","title":"Growth Hormone Replacement Therapy for Retried Professional Football Players","status":"RECRUITING","sponsor":"Center for Neurological Studies","startDate":"2019-10-08","conditions":"TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury","enrollment":42},{"nctId":"NCT01626833","phase":"PHASE2, PHASE3","title":"Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-03","conditions":"Anorexia Nervosa, Interruption of Growth, Delayed Puberty","enrollment":15},{"nctId":"NCT02229851","phase":"PHASE3","title":"Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-10-31","conditions":"Growth Hormone Disorder, Adult Growth Hormone Deficiency","enrollment":301},{"nctId":"NCT00082628","phase":"PHASE3","title":"Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2004-05-28","conditions":"HIV Infections, Lipodystrophy","enrollment":326},{"nctId":"NCT00931476","phase":"PHASE1","title":"A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2000-04-06","conditions":"Growth Hormone Disorder, Adult Growth Hormone Deficiency, Healthy","enrollment":86},{"nctId":"NCT01034202","phase":"PHASE1","title":"Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-08","conditions":"Growth Hormone Disorder, Healthy","enrollment":56},{"nctId":"NCT00294164","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2001-03","conditions":"Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS), Human Immunodeficiency Virus Infections","enrollment":245},{"nctId":"NCT00533221","phase":"PHASE2","title":"Pilot Study of Growth Hormon to Treat SMA Typ II and III","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2007-10","conditions":"Muscular Atrophy, Spinal","enrollment":20},{"nctId":"NCT01077960","phase":"PHASE3","title":"Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2005-02","conditions":"Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome","enrollment":126},{"nctId":"NCT00933686","phase":"PHASE3","title":"Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2007-12","conditions":"Fibromyalgia","enrollment":113},{"nctId":"NCT00133354","phase":"PHASE2, PHASE3","title":"Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2001-11","conditions":"Hypopituitarism","enrollment":53},{"nctId":"NCT00781547","phase":"PHASE3","title":"Growth Hormone Treatment in Men With High Risk of Developing Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Göteborg University","startDate":"1999-01","conditions":"Abdominal Obesity, Metabolic Syndrome, Obesity","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo and Saizen®","genericName":"Placebo and Saizen®","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Saizen® is a recombinant human growth hormone that replaces or supplements endogenous growth hormone to promote growth and metabolic effects. Used for Growth hormone deficiency (likely indication based on Saizen® approved uses), Short stature or growth disorders (potential Phase 3 indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}